Navigation Links
BioGlue(R) Surgical Adhesive Hits 500,000 Procedure Milestone Worldwide, Company Data Indicates
Date:6/29/2009

ATLANTA, June 29 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that, according to company data, CryoLife's BioGlue(R) Surgical Adhesive has been used in more than 500,000 surgical procedures throughout the world since its introduction into the international market in 1998 and in the United States in 2001. BioGlue is a leading surgical adhesive used in cardiovascular surgeries worldwide.

"I have been using BioGlue since its market introduction almost 10 years ago," said Dr. John W. Fehrenbacher, Methodist Hospital, Indianapolis, Ind. "I have utilized BioGlue in over 1,000 patients undergoing a variety of cardiac procedures including valve replacements, aneurysm repair, and aortic dissection repair. I find that BioGlue is safe, easy to use, and because of its effectiveness at reducing anastomotic bleeding, has allowed me to change the way I perform many of my aortic aneurysm procedures."

A two-component adhesive, BioGlue creates a flexible, mechanical seal, independent of the body's clotting mechanism. BioGlue comes in a self-contained, disposable syringe that is available in 2mL, 5mL, and 10mL volumes. Ergonomically designed, the delivery system allows for simple preparation and ease of use.

"The use of BioGlue has continued to grow as surgeons around the globe have experienced its highly effective sealing properties during complex procedures," said Steven G. Anderson, president and CEO of CryoLife. "We anticipate the continued adoption of BioGlue as an essential component of the surgical toolkit, particularly as it is approved for additional indications."

BioGlue is currently approved by the U.S. Food and Drug Administration as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. It is used most commonly in the U.S. for complex cardiovascular procedures involving aortic aneurysms, valve replacements and aortic dissections, as well as peripheral vascular procedures, such as carotid endarterectomy, and arteriovenous access.

In the international market, BioGlue is indicated for use in cardiac and vascular procedures as well as for repair of other soft tissues, including pulmonary, genitourinary, dural, alimentary (esophageal, gastrointestinal, and colorectal), and other abdominal tissues (pancreatic, splenic, hepatic, biliary). It is also used in the fixation of surgical meshes in hernia repair.

BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company's CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed or malfunctioning native pulmonary valves. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. CryoLife distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding BioGlue's anticipated continued adoption and approval for additional indications. These risks and uncertainties include that we are significantly dependent on revenues from BioGlue and there are a variety of risks affecting BioGlue; the risk of not obtaining additional approvals on a timely basis or at all due to testing results proving disappointing, additional costs, and requirements or trials that might be imposed; the risk that adoption by doctors can be negatively impacted by numerous factors including adverse publicity and competing products; that uncertainties related to patents and protection of proprietary technology may adversely affect the value of our intellectual property; we may not be successful in obtaining necessary clinical results and additional regulatory approvals for products and services in development, and our new products and services may not achieve market acceptance; and that rapid technological change could cause our services and products to become obsolete. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K filing for the year ended December 31, 2008, our most recent Form 10-Q, and the Company's other SEC filings. The Company does not undertake to update its forward-looking statements.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.

    CONTACT:
    D. Ashley Lee                                       Katie Brazel
    Executive Vice President, Chief Financial           Fleishman Hillard
     Officer and Chief Operating Officer                Phone: 404-739-0150
    Phone: 770-419-3355


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Richard A. Meier Appointed to STAAR Surgical Board of Directors
2. McKesson Medical-Surgical Selects DataLens System to Automate Product Data Mastering
3. St. Charles Surgical Hospital Announces Dedicated Lymphedema Treatment Program
4. STAAR Surgical Completes Common Stock Offering
5. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
6. Torn Surgical Gloves Put Patients at Risk for Infection
7. Ambulatory Surgery Centers Pivotal in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings
8. Study finds segregation decreases access to surgical care for minorities
9. Three-Year Agreement for Surgical Instrument Repair Services
10. PEAK Surgical Announces First Use of PEAK PlasmaBlade(TM) in Europe
11. Baylor Dallas Opens Nations First Neurosurgical OR Suite Featuring BrainSUITE iMRI, GE Healthcare MR Surgical Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
(Date:2/23/2017)... San Ramon, CA (PRWEB) , ... February 23, 2017 , ... ... Kaplan, MD, FACP, FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and ... served as the chairman and CEO of the Virginia Mason Health System in Seattle ...
(Date:2/23/2017)... ... 2017 , ... Carlos Gutierrez has lived his spiritual life hardly ... which is the purpose of everyone in this universe. As Gutierrez sees the need ... Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leverages advanced data analytics to accurately understand each Medicare Advantage member’s risk, ... a given population. This new solution helps transform the HCC Risk Adjustment ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  As National Nutrition ... addition, the Company is helping people live healthier ... customized prescription savings programs in all 50 states ... Assistance Program  and  California Prescription Assistance Program . ... Columbia University for nutritious eating habits: ...
(Date:2/23/2017)... MARIETTA, Ga., Feb. 23, 2017  MiMedx Group, Inc. ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of ... quarter and full year ended December 31, 2016. ... Revenue is a 31% increase over full year ...
(Date:2/23/2017)... Korea , Feb. 23, 2017 LG Innotek today ... LED for sterilization applications. As its sterilization performance is 1.5 times ... the short wavelength ultraviolet rays in the range of 200 -- 280nm, ... proliferation of bacteria by destroying their DNA. LG Innotek,s product emits ... ...
Breaking Medicine Technology: